Literature DB >> 31812654

Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing.

Britt Christensen1, Jonathan Erlich2, Peter R Gibson3, Jerrold R Turner4, John Hart4, David T Rubin2.   

Abstract

BACKGROUND & AIMS: Deep remission, based on clinical remission and evidence of healing during endoscopic evaluation, are goals of medical treatments for Crohn's disease (CD). We investigated whether histologic healing is associated with outcomes of patients with CD ileitis.
METHODS: We performed a retrospective study of 101 patients with CD (52% male) isolated to the terminal ileum who had a colonoscopy between September 2005 and June 2015. Our analysis included patients in clinical remission at colonoscopy who had biopsies collected from colon and ileum. The ileum was evaluated for endoscopic healing (no ulceration) and histologic evidence of healing (no active inflammation, erosions, ulceration, or neutrophil infiltration). We compared times of clinical relapse-free survival, medication escalation, corticosteroid use, or hospitalization secondary to disease activity between patients with and without histological and endoscopic healing, followed for a median 21 months. We identified factors associated with survival using Kaplan Meier analysis and Cox proportional hazard model.
RESULTS: At ileo-colonoscopy, 63% of patients had endoscopic healing and 55% had histologic evidence of healing. The level of agreement between endoscopic and histologic activity was fair (62%, K = 0.2250, P = .0064). Forty-two patients had clinical relapse, 45 had medication escalation, 30 required corticosteroids, and 17 were hospitalized (3 required surgery). On multivariate analysis, only histologic healing was associated with decreased risk of clinical relapse (hazard ratio [HR], 2.05; 95% CI, 1.07-3.94; P = .031), medication escalation (HR, 2.17; 95% CI, 1.2-3.96; P = .011), and corticosteroid use (HR, 2.44; 95% CI, 1.17-5.09; P = .018). No factors were associated with hospitalization.
CONCLUSIONS: In patients with ileal CD in clinical remission, histologic healing but not endoscopic healing is associated with decreased risk of clinical relapse, medication escalation, or corticosteroid use.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Histology; Histopathology; Inflammatory Bowel Disease; Mucosal Healing; Prognostic Factor

Year:  2019        PMID: 31812654      PMCID: PMC7586726          DOI: 10.1016/j.cgh.2019.11.056

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  29 in total

1.  Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.

Authors:  Karel Geboes; Paul Rutgeerts; Ghislain Opdenakker; Allan Olson; Kamlesh Patel; Carrie L Wagner; Colleen W Marano
Journal:  Curr Med Res Opin       Date:  2005-11       Impact factor: 2.580

2.  Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark.

Authors:  Tine Jess; Lene Riis; Ida Vind; Karen Vanessa Winther; Sixten Borg; Vibeke Binder; Ebbe Langholz; Ole Østergaard Thomsen; Pia Munkholm
Journal:  Inflamm Bowel Dis       Date:  2007-04       Impact factor: 5.325

3.  A simple index of Crohn's-disease activity.

Authors:  R F Harvey; J M Bradshaw
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

4.  A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease.

Authors:  Bita V Naini; Galen Cortina
Journal:  Hum Pathol       Date:  2012-06-14       Impact factor: 3.466

5.  Adalimumab induces deep remission in patients with Crohn's disease.

Authors:  Jean-Frédéric Colombel; Paul J Rutgeerts; William J Sandborn; Mei Yang; Anne Camez; Paul F Pollack; Roopal B Thakkar; Anne M Robinson; Naijun Chen; Parvez M Mulani; Jingdong Chao
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-12       Impact factor: 11.382

6.  Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.

Authors:  Katherine Li; Joshua R Friedman; Daphne Chan; Paul Pollack; Feifei Yang; Douglas Jacobstein; Carrie Brodmerkel; Christopher Gasink; Brian G Feagan; William J Sandborn; Paul Rutgeerts; Gert De Hertogh
Journal:  Gastroenterology       Date:  2019-07-04       Impact factor: 22.682

Review 7.  Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.

Authors:  L Vuitton; L Peyrin-Biroulet; J F Colombel; B Pariente; G Pineton de Chambrun; A J Walsh; J Panes; S P L Travis; J Y Mary; P Marteau
Journal:  Aliment Pharmacol Ther       Date:  2017-01-23       Impact factor: 8.171

8.  Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes.

Authors:  Britt Christensen; Stephen B Hanauer; Jonathan Erlich; Olufemi Kassim; Peter R Gibson; Jerrold R Turner; John Hart; David T Rubin
Journal:  Clin Gastroenterol Hepatol       Date:  2017-02-24       Impact factor: 11.382

9.  Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

Authors:  Fabian Schnitzler; Herma Fidder; Marc Ferrante; Maja Noman; Ingrid Arijs; Gert Van Assche; Ilse Hoffman; Kristel Van Steen; Séverine Vermeire; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2009-09       Impact factor: 5.325

Review 10.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

View more
  12 in total

1.  A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data.

Authors:  Jordan E Axelrad; Michael C Sachs; Jonas F Ludvigsson; Ola Olén
Journal:  Clin Epidemiol       Date:  2020-10-09       Impact factor: 4.790

2.  Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission.

Authors:  Hyuk Yoon; Sushrut Jangi; Parambir S Dulai; Brigid S Boland; Vipul Jairath; Brian G Feagan; William J Sandborn; Siddharth Singh
Journal:  Inflamm Bowel Dis       Date:  2021-07-27       Impact factor: 5.325

3.  High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study.

Authors:  Aze Wilson; Bethany Choi; Michael Sey; Terry Ponich; Melanie Beaton; Richard B Kim
Journal:  BMC Gastroenterol       Date:  2021-02-18       Impact factor: 3.067

4.  Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease.

Authors:  Katia Farias E Silva; Hayandra F Nanini; Cynthia Machado Cascabulho; Siane L B Rosas; Patricia T Santana; Antonio José de V Carneiro; Elias Anaissie; Marcio Nucci; Heitor Siffert Pereira de Souza
Journal:  World J Gastroenterol       Date:  2021-03-07       Impact factor: 5.742

5.  Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease.

Authors:  Corinna Lang-Schwarz; Abbas Agaimy; Raja Atreya; Christoph Becker; Silvio Danese; Jean-François Fléjou; Nikolaus Gaßler; Heike I Grabsch; Arndt Hartmann; Kateřina Kamarádová; Anja A Kühl; Gregory Y Lauwers; Alessandro Lugli; Iris Nagtegaal; Markus F Neurath; Georg Oberhuber; Laurent Peyrin-Biroulet; Timo Rath; Robert Riddell; Carlos A Rubio; Kieran Sheahan; Herbert Tilg; Vincenzo Villanacci; Maria Westerhoff; Michael Vieth
Journal:  Virchows Arch       Date:  2020-12-29       Impact factor: 4.064

6.  Validation of the 'Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn´s Disease.

Authors:  Corinna Lang-Schwarz; Miriam Angeloni; Abbas Agaimy; Raja Atreya; Christoph Becker; Theresa Dregelies; Silvio Danese; Jean-François Fléjou; Nikolaus Gaßler; Heike I Grabsch; Arndt Hartmann; Kateřina Kamarádová; Anja A Kühl; Gregory Y Lauwers; Alessandro Lugli; Iris Nagtegaal; Markus F Neurath; Georg Oberhuber; Laurent Peyrin-Biroulet; Timo Rath; Robert Riddell; Carlos A Rubio; Kieran Sheahan; Britta Siegmund; Herbert Tilg; Vincenzo Villanacci; Maria Westerhoff; Fulvia Ferrazzi; Michael Vieth
Journal:  J Crohns Colitis       Date:  2021-10-07       Impact factor: 9.071

Review 7.  Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art.

Authors:  Edoardo Vespa; Ferdinando D'Amico; Mauro Sollai; Mariangela Allocca; Federica Furfaro; Alessandra Zilli; Arianna Dal Buono; Roberto Gabbiadini; Silvio Danese; Gionata Fiorino
Journal:  J Clin Med       Date:  2022-02-11       Impact factor: 4.241

8.  Developing a Neural Network Model for a Non-invasive Prediction of Histologic Activity in Inflammatory Bowel Diseases.

Authors:  Iolanda Valentina Popa; Mircea Diculescu; Catalina Mihai; Cristina Cijevschi Prelipcean; Alexandru Burlacu
Journal:  Turk J Gastroenterol       Date:  2021-03       Impact factor: 1.852

9.  Outcomes of Primary Ileocolic Resection for Pediatric Crohn Disease in the Biologic Era.

Authors:  Elizabeth A Spencer; Lauren Jarchin; Priya Rolfes; Sergey Khaitov; Alexander Greenstein; Marla C Dubinsky
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-12-01       Impact factor: 2.839

10.  Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease.

Authors:  Suruchi K Batra; Christopher R Heier; Lina Diaz-Calderon; Christopher B Tully; Alyson A Fiorillo; John van den Anker; Laurie S Conklin
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.